Dr. Wasserman is the Chief Medical Officer at Northern Biologics as of December, 2016. Dr. Wasserman’s expertise lies in oncology translational medicine, including preclinical, clinical, biomarker and companion diagnostic drug development.
From May 2014 through November 2016, Dr. Wasserman was responsible for leading the medical strategy for Oncology and Malignant Hematology as the Global Therapeutic Area Head for Covance, the CRO division of LabCorp. He was the leader for the physician group that monitors global and regional Oncology trials for clients. He led the cross -business unit team responsible for educating employees and promoting their Immuno-Oncology expertise and capabilities as part of a corporate strategic initiative.
Before joining Covance, Dr. Wasserman spent 15 years in the pharmaceutical industry, most recently at Hoffmann-La Roche as Site Head of Academic Alliances, Pharma Research and Early Development (pRED) for the Translational Clinical Research Center. He also served as Vice President and Personalized Healthcare Strategic Expert for Roche pRED Oncology, where he was responsible for the personalized healthcare strategy across the preclinical and early clinical development portfolio. In addition, as Vice President and Global Head, Translational Medicine for Roche pRED Oncology, he was responsible for bridging discovery and clinical research through the development of translational medicine strategies, conducting early-phase trials, and supporting the personalized healthcare objectives of the organization. Prior to his employment at Roche, he was the Deputy Director of the Oncology Biomarker group aat Novartis after starting his pharmaceutical career at Merck.
Dr. Wasserman earned his M.D. from Johns Hopkins University School of Medicine, and completed his Pediatric Residency and Pediatric Hematology-Oncology fellowship training at The Children’s Hospital of Philadelphia, University of Pennsylvania. After completing his training, he stayed on as an Assistant Professor for nine years.